08Mar 2022
Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studies

Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studies

Hidradenitis suppurativa (HS) is a chronic, painful, inflammatory skin condition that can ultimately lead to irreversible tissue damage and scar formation. INCB054707 was well tolerated, with responses observed in patients with moderate‐to‐severe HS. The safety and efficacy findings from these studies demonstrate proof of concept for JAK1 inhibition in HS.

  • #dermatology

Like

Save

Share